$0.40
10.74%
Nasdaq, Nov 17, 04:00 pm EST. Closed.
ISIN
US00972D1054
Symbol
AKBA

Akebia Therapeutics, Inc. Stock price

$0.40
-0.28 41.13% 1M
-0.61 60.36% 6M
-1.21 75.13% YTD
-1.36 77.25% 1Y
-0.60 59.96% 3Y
-2.40 85.70% 5Y
-8.58 95.54% 10Y
-26.29 98.50% 20Y
Nasdaq, Closing price Tue, Nov 17 2026
-0.05 10.74%
ISIN
US00972D1054
Symbol
AKBA
Industry

Is Akebia Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$124.6m
Enterprise Value
$161.3m
Net debt
$36.8m
Cash
$155.6m
Shares outstanding
271.7m
Valuation
P/E
negative
P/S | estimate
0.6 | 0.7
EV/Sales | estimate
0.7 | 0.9
EV/FCF | ex SBC
5.5 | 10.0
P/B
5.0
Financial Health
Equity Ratio
8.7%
Return on Equity
-16.4%
ROCE
-3.0%
ROIC
-3.4%
Debt/Equity
7.7
Share-Based Compensation & Dilution
SBC | % of Revenue
$13.3m | 6.1%
SBC as % of FCF
45.2%
SBC Growth 1Y
62.1%
Share Count Growth 1Y
3.3%
Shareholder Yield
-3.3%
Financials
Revenue | estimate
$219.1m | $177.1m
EBITDA
$-4.1m
EBIT
$-5.7m
Net Income
$-29.7m
Free Cash Flow | ex SBC
$29.5m | $16.1m
Growth
Revenue | estimate
7.5% | -25.0%
EBITDA
-119.1%
EBIT
-258.2%
Net Income
18.7%
Free Cash Flow
1,255.3%
Margin
Gross
81.5%
EBITDA
-1.9%
EBIT
-2.6%
Net
-13.5%
Free Cash Flow | ex SBC
13.5% | 7.4%
More
EPS
$-0.1
FCF per Share
$0.1
Short interest
9.9%
Employees
194
Rev per Employee
$1.2m

Akebia Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Akebia Therapeutics, Inc. forecast:

10x Buy
83%
2x Hold
17%

Analyst Opinions

12 Analysts have issued a Akebia Therapeutics, Inc. forecast:

Buy
83%
Hold
17%

Akebia Therapeutics, Inc. Events

Past Events
NOV
5
Q3 2026 Earnings Call
12 days ago
AUG
5
Q2 2026 Earnings Call
3 months ago
MAY
7
Q1 2026 Earnings Call
6 months ago
APR
2
Special Call - Akebia Therapeutics, Inc.
8 months ago
MAR
9
Leerink Global Healthcare Conference 2026
8 months ago
FEB
26
Q4 2025 Earnings Call
9 months ago
FEB
12
Guggenheim Securities Emerging Outlook: Biotech Summit 2026
9 months ago
NOV
10
Q3 2025 Earnings Call
about one year ago

Financial data from Akebia Therapeutics, Inc.

Jun '26
+/-
%
219 219
8% 8%
100%
- Direct Costs 40 40
17% 17%
18%
179 179
6% 6%
82%
- Selling and Administrative Expenses 114 114
7% 7%
52%
- Research and Development Expense 70 70
72% 72%
32%
-4.13 -4.13
119% 119%
-2%
- Depreciation and Amortization 1.55 1.55
91% 91%
1%
EBIT (Operating Income) EBIT -5.68 -5.68
258% 258%
-3%
Net Profit -30 -30
19% 19%
-14%

In millions USD.

Don't miss a Thing! We will send you all news about Akebia Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Akebia Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
●
about one hour ago
New patent with term until 2043 further strengthens patent portfolio WALTHAM, Mass., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that a new patent has been granted for Vafseo® (vadadustat), strengthening Akebia's vadadustat intellectual property...
Neutral
GlobeNewsWire
●
one day ago
Initial $60 million tranche fully funded, proceeds of which were used to fully repay $55 million BlackRock loan facility
More Akebia Therapeutics, Inc. News

Company Profile

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Head office United States
CEO Mr. Butler
Employees 194
Founded 2007
Website akebia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today